Lung Cancer Clinical Trials in Nashville

Showing 721-740 of 799 trials

Molecular Markers in Predicting Lung Cancer Development Using Tissue Samples From Healthy Participants

NCT00899457

RATIONALE: Studying samples of blood, urine, sputum, mouth cells, and bronchial tissue from healthy participants in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about the development of cancer. PURPOSE: This laboratory study is looking for molecular markers in predicting lung cancer development using tissue samples from healthy participants.

Healthy, no Evidence of DiseaseLung Cancer

Vanderbilt-Ingram Cancer Center37 participantsStarted Apr 2008

Nashville, Tennessee, United States • Nashville, Tennessee, United States • Nashville, Tennessee, United States

TERMINATEDPhase 3< 1 mile

Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer

NCT00004859

This randomized phase III trial is studying carboplatin, paclitaxel, radiation therapy, and thalidomide to see how well they work compared to carboplatin, paclitaxel, and radiation therapy alone in treating patients with newly diagnosed stage III non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of non-small cell lung cancer by stopping blood flow to the tumor. It is not yet known if combination chemotherapy plus radiation therapy is more effective with or without thalidomide.

Lung Cancer

National Cancer Institute (NCI)589 participantsStarted Jan 2000

Fort Smith, Arkansas, United States • Modesto, California, United States • Salinas, California, United States +233 more locations

Molecular Markers in Predicting Lung Cancer Development Using Tissue Samples From Healthy Participants

Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer

Lung Cancer Trials in Other Cities

National Lung Screening Trial (NLST) Screening

Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: AEGIS CLIA

Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer

S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors

Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer

Marimastat in Treating Patients With Stage III Non-small Cell Lung Cancer

Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC

A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.

Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults

Biological Therapy in Previously Treated Patients With Non-small Cell Lung Cancer

Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC

VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer

Positron Emission Tomography Scan and CT Scan in Planning Radiation Therapy for Patients With Stage II or Stage III Non-Small Cell Lung Cancer

Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer

Other Conditions in Nashville